A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3855

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 vaccine
OTHER: Control

Sponsor

GlaxoSmithKline